Subscribe
shutterstock_1533140117_michael_vi
Michael Vi / Shutterstock.com
13 February 2020AmericasRory O'Neill

10x Genomics strikes back in Bio-Rad saga with USITC ban

US biotechnology company 10x Genomics has won an import ban against its rival Bio-Rad Laboratories in a long-running patent dispute.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Bio-Rad and 10X Genomics end patent fight with new licensing deal
29 July 2021   Bio-Rad Laboratories has settled its long-running dispute with 10X Genomics over patents covering genetic analysis tech and both companies have negotiated an agreement to cross-license their products.
Big Pharma
Bio-Rad asks for review of DNA patent ruling
17 June 2021   Bio-Rad has asked the US Court of Appeals for the Federal Circuit to review its prior decisions that affirmed Bio-Rad had infringed three 10X Genomics patents.
Big Pharma
Federal Circuit upholds another ITC decision in 10X vs Bio-Rad
3 June 2021   The US Court of Appeals for the Federal Circuit has upheld a decision from the US International Trade Commission that found 10X Genomics infringed on two Bio-Rad Laboratories gene sequencing patents.


Editor's picks

Latham steps into dispute over $6bn treatment, replacing Kirkland
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025

Editor's picks

Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025

More on this story

Biotechnology
Bio-Rad and 10X Genomics end patent fight with new licensing deal
29 July 2021   Bio-Rad Laboratories has settled its long-running dispute with 10X Genomics over patents covering genetic analysis tech and both companies have negotiated an agreement to cross-license their products.
Big Pharma
Bio-Rad asks for review of DNA patent ruling
17 June 2021   Bio-Rad has asked the US Court of Appeals for the Federal Circuit to review its prior decisions that affirmed Bio-Rad had infringed three 10X Genomics patents.
Big Pharma
Federal Circuit upholds another ITC decision in 10X vs Bio-Rad
3 June 2021   The US Court of Appeals for the Federal Circuit has upheld a decision from the US International Trade Commission that found 10X Genomics infringed on two Bio-Rad Laboratories gene sequencing patents.

More on this story

Biotechnology
Bio-Rad and 10X Genomics end patent fight with new licensing deal
29 July 2021   Bio-Rad Laboratories has settled its long-running dispute with 10X Genomics over patents covering genetic analysis tech and both companies have negotiated an agreement to cross-license their products.
Big Pharma
Bio-Rad asks for review of DNA patent ruling
17 June 2021   Bio-Rad has asked the US Court of Appeals for the Federal Circuit to review its prior decisions that affirmed Bio-Rad had infringed three 10X Genomics patents.
Big Pharma
Federal Circuit upholds another ITC decision in 10X vs Bio-Rad
3 June 2021   The US Court of Appeals for the Federal Circuit has upheld a decision from the US International Trade Commission that found 10X Genomics infringed on two Bio-Rad Laboratories gene sequencing patents.

More features

Weil adds two more litigators from larger rival
Why the PTAB’s new expedited filing dates for AIA petitions is positive
Ninth Circuit revives trade secrets claims in DNA-sequencing spat
Latham steps into dispute over $6bn treatment, replacing Kirkland
Patent pollution: Emissions charter aims to clean up IP
Why Trump’s revenue-raising patent plan is riddled with problems
Harvard’s patent portfolio at risk as Trump turns up the pressure
Weil adds leaders from Latham to head up tech and life sciences